Details of the Drug

General Information of Drug (ID: DMTW3R8)

Drug Name

Sulfadiazine

Synonyms

Adiazin; Adiazine; CocoDiazine; Codiazine; Cremodiazine; Cremotres; Debenal; Deltazina; Diazin; Diazolone; Diazovit; Diazyl; Eskadiazine; Liquadiazine; Microsulfon; Neazine; Neotrizine; Palatrize; Piridisir; Pirimal; Pyrimal; Quadetts; Quadramoid; Sanodiazine; Solfadiazina; Spofadrizine; Sterazine; Sulfadiazene; Sulfadiazin; Sulfadiazina; Sulfadiazinum; Sulfanilamidopyrimidine; Sulfapirimidin; Sulfapyrimidin; Sulfapyrimidine; Sulfatryl; Sulfazine; Sulfolex; Sulfonsol; Sulfose; Sulphadiazine; Terfonyl; Theradiazine; Trifonamide; Trisem; Truozine; Honey diazine; Solfadiazina [DCIT]; Sulfapyrimidin [German]; Sulfonamides Duplex; Sulphadiazine E; Triple Sulfas; Zinc Sulfadiazine; A 306; RP 2616; A-306; Coco-Diazine; Lantrisul (TN); Lipo-Diazine; Lipo-Levazine; Metha-Meridiazine; Neotrizine (TN); Pecta-Diazine; RBPI21 & Sulfa; Sulfadiazina [INN-Spanish]; Sulfadiazine (TN); Sulfadiazine, Zinc; Sulfadiazinum [INN-Latin]; Sulfaloid (TN); Sulfonamides Duplex (TN); Sulfose (TN); Terfonyl (TN); Tri-Sulfameth; Triple Sulfa (TN); Triple Sulfas (TN); Triple Sulfoid (TN); Trisulfapyrimidine, oral suspension; A-306 (VAN); CRL-8131 & Sulfadiazine; Di-Azo-Mul; Mixture of sulfadiazine, sulfamerazine, and sulfamethazine; Pecta-diazine, suspension; S. N. 112; S.N. 112; Sulfadiazine [USAN:INN:JAN]; Thi-Di-Mer; N(1)-2-pyrimidinylsulfanilamide; N(1)-2-pyrimidylsulfanilamide; N(sup 1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidylsulfanilamide; N-(2-Pyrimidinyl)sulfanilamide; Recombinant bactericidal/permeability-increasing protein & Sulfadiazine; Sulfa-Triple #2 (TN); Sulfadiazine (JAN/USP/INN); N1-(Pyrimidin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyrimidinyl-(8CI); Adiazin, Adiazine, Debenal, Liquadiazine, Microsulfon, Sulfazine, Sulfolex, Sulfadiazine; 2-Sulfanilamido-pyrimidine; 2-Sulfanilamidopyrimidin; 2-Sulfanilamidopyrimidin [German]; 2-Sulfanilamidopyrimidine; 2-Sulfanilylaminopyrimidine; 2-Sulfapyrimidine; 4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDE; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-2-pyrimidinyl-benzenesulfonamide; SDZ

Indication

Disease Entry	ICD 11	Status	REF
Rheumatic fever	1B40-1B42	Approved	[1]
Skin ulcer	ME60.Z	Approved	[2]
Ulcerative colitis	DD71	Approved	[2]
Chorioretinitis	N.A.	Investigative	[2]
Congenital toxoplasmosis	N.A.	Investigative	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antiinfective Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

250.28

Logarithm of the Partition Coefficient (xlogp)

-0.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [3]
Bioavailability: 90% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 0.55 mL/min/kg [5]
Elimination: 57% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 7 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 684.94708 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.44% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.29 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.13 mg/mL [3]

Chemical Identifiers

Formula: C10H10N4O2S
IUPAC Name: 4-amino-N-pyrimidin-2-ylbenzenesulfonamide
Canonical SMILES: C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N
InChI: InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
InChIKey: SEEPANYCNGTZFQ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5215
ChEBI ID: CHEBI:9328
CAS Number: 68-35-9
DrugBank ID: DB00359
TTD ID: D05LKP
INTEDE ID: DR1509
ACDINA ID: D00642

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Dihydropteroate synthetase (Bact folP)	TT4ILYC	DHPS_ECOLI	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[8]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[9]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[10]
RNA cytidine acetyltransferase (hALP)	DEZV4AP	NAT10_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Arylamine N-acetyltransferase 2 (NAT2)	OTBPDQOY	ARY2_HUMAN	Biotransformations	[11]
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Biotransformations	[11]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Biotransformations	[11]
Glutamate receptor ionotropic, NMDA 1 (GRIN1)	OTZ5YBO8	NMDZ1_HUMAN	Gene/Protein Processing	[12]
Lactoperoxidase (LPO)	OTJ9QKX9	PERL_HUMAN	Gene/Protein Processing	[12]
Oligodendrocyte transcription factor 2 (OLIG2)	OTMCN6D3	OLIG2_HUMAN	Gene/Protein Processing	[12]
Serine/threonine-protein kinase mTOR (MTOR)	OTHH8KU7	MTOR_HUMAN	Gene/Protein Processing	[12]
SH3 and multiple ankyrin repeat domains protein 2 (SHANK2)	OTSQTPFQ	SHAN2_HUMAN	Gene/Protein Processing	[12]
Sodium-dependent serotonin transporter (SLC6A4)	OT6FGDLW	SC6A4_HUMAN	Gene/Protein Processing	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sulfadiazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[13]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Sulfadiazine and Repaglinide.	Acute diabete complication [5A2Y]	[14]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Sulfadiazine and Tolazamide.	Acute diabete complication [5A2Y]	[14]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Sulfadiazine and Nateglinide.	Acute diabete complication [5A2Y]	[14]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Sulfadiazine and Insulin-glulisine.	Acute diabete complication [5A2Y]	[14]
Acetohexamide	DMR6N7H	Moderate	Increased risk of hypoglycemia by the combination of Sulfadiazine and Acetohexamide.	Acute diabete complication [5A2Y]	[14]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Sulfadiazine and Insulin-aspart.	Acute diabete complication [5A2Y]	[15]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Sulfadiazine and Glipizide.	Acute diabete complication [5A2Y]	[14]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[16]
Montelukast	DMD157S	Moderate	Decreased metabolism of Sulfadiazine caused by Montelukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[17]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[18]
Anisindione	DM2C48U	Major	Increased plasma concentration of Sulfadiazine and Anisindione due to competitive binding of plasma proteins.	Coagulation defect [3B10]	[19]
Mycophenolic acid	DMRBMAU	Moderate	Altered absorption of Sulfadiazine due to GI flora changes caused by Mycophenolic acid.	Crohn disease [DD70]	[20]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Cannabidiol.	Epileptic encephalopathy [8A62]	[21]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[22]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Sulfadiazine caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[25]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Sulfadiazine and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[26]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Sulfadiazine caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[27]
Methotrexate	DM2TEOL	Moderate	Increased plasma concentration of Sulfadiazine and Methotrexate due to competitive binding of plasma proteins.	Leukaemia [2A60-2B33]	[28]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Sulfadiazine and Porfimer Sodium.	Lung cancer [2C25]	[29]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[30]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Idelalisib.	Mature B-cell leukaemia [2A82]	[31]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Clofarabine.	Mature B-cell lymphoma [2A85]	[32]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Sulfadiazine and Methoxsalen.	Mycosis fungoides [2B01]	[13]
Diclofenac	DMPIHLS	Moderate	Decreased metabolism of Sulfadiazine caused by Diclofenac mediated inhibition of CYP450 enzyme.	Osteoarthritis [FA00-FA05]	[13]
Prilocaine	DMI7DZ2	Major	Increased risk of methemoglobinemia by the combination of Sulfadiazine and Prilocaine.	Pain [MG30-MG3Z]	[33]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Sulfadiazine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[34]
Verteporfin	DMIY6DB	Moderate	Increased risk of photosensitivity reactions by the combination of Sulfadiazine and Verteporfin.	Psoriasis [EA90]	[21]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Sulfadiazine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[35]
Vardenafil	DMTBGW8	Moderate	Decreased metabolism of Sulfadiazine caused by Vardenafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[36]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[21]
Epirubicin	DMPDW6T	Moderate	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[13]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Sulfadiazine and Naltrexone.	Substance abuse [6C40]	[37]
Warfarin	DMJYCVW	Major	Increased plasma concentration of Sulfadiazine and Warfarin due to competitive binding of plasma proteins.	Supraventricular tachyarrhythmia [BC81]	[19]
Mycophenolate mofetil	DMPQAGE	Moderate	Altered absorption of Sulfadiazine due to GI flora changes caused by Mycophenolate mofetil.	Transplant rejection [NE84]	[20]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Sulfadiazine and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[14]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Sulfadiazine and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[14]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Sulfadiazine and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[14]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Sulfadiazine and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[14]
Ganciclovir	DM1MBYQ	Moderate	Increased risk of nephrotoxicity by the combination of Sulfadiazine and Ganciclovir.	Virus infection [1A24-1D9Z]	[13]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Sulfadiazine and Valganciclovir.	Virus infection [1A24-1D9Z]	[13]
-----------


⏷ Show the Full List of 43 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Docusate sodium	E00563	23673837	Surfactant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Sulfadiazine 500 mg tablet	500 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Sulfadiazine FDA Label
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94.
8	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
9	Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
10	Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes. Life Sci. 2005 May 27;77(2):205-19.
11	Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
12	Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
13	Cerner Multum, Inc. "Australian Product Information.".
14	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
15	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
16	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
17	Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT "Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast." Clin Pharmacol Ther (2010):. [PMID: 20592724]
18	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
19	Cook DE, Ponte CD "Suspected trimethoprim sulfamethoxazole induced hypoprothrombinemia." J Fam Pract 39 (1994): 589-91. [PMID: 7798864]
20	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
21	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
23	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
24	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
25	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
26	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
27	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
28	Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J "Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis." Clin Pharmacokinet 30 (1996): 194-210. [PMID: 8882301]
29	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
30	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
31	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
32	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
33	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
34	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
35	Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
36	Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
37	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.